Peripheral blood reverse transcription PCR assay for prostate stem cell antigen correlates with androgen‐independent progression in advanced prostate cancer
Peripheral blood reverse transcription PCR assay for prostate stem cell antigen correlates with androgen‐independent progression in advanced prostate cancer
复制标题
DOI：
10.1002/ijc.26459
复制
发表时间：
2012-08
影响因子：
6.4
通讯作者：
Zhigang Zhao;G. Zeng;W. Ma;Li-li Ou;Ye-ping Liang
中科院分区：
文献类型：
--
作者：
Zhigang Zhao;G. Zeng;W. Ma;Li-li Ou;Ye-ping Liang
最近的研究表明，前列腺干细胞抗原（PSCA）mRNA在外周血中的阳性与前列腺癌（PCa）的疾病进展相关。我们的研究是在接受雄激素剥夺治疗（ADT）的晚期PCa患者队列中评估外周血PSCA状态与雄激素非依赖性进展（AIP）之间的相关性。通过逆转录酶聚合酶链反应（RT-PCR）测定了116例接受原发性ADT治疗的局部晚期或转移性PCa患者和40例健康对照的外周血样本中的PSCA mRNA。Kaplan-Meier和考克斯比例风险法用于评估AIP的潜在预测因素。116例患者中有37例（31.9%）的治疗前RT-PCR-PSCA呈阳性。所有健康志愿者PSCA mRNA均为阴性。尽管Gleason评分≤7的47例患者中有7例（14.9%）PSCA阳性，但Gleason评分>7的69例患者中有30例（43.5%）PSCA阳性（p = 0.016）。48例转移性PCa患者中有28例（58.3%）检测到PSCA mRNA，而68例局部晚期疾病患者中有9例（13.2%）检测到PSCA mRNA（p = 0.012）。在中位随访期35.4个月（范围：4-78个月）内，59例（50.9%）患者发生AIP。与PSCA阳性患者相比，PSCA阴性患者的缓解时间显著更长（对数秩检验：p < 0.001）。多因素考克斯回归分析进一步显示PSCA阳性者发生AIP的风险显著增加（HR = 4.303，95%CI：3.761-7.482，p < 0.001）。外周血中治疗前RT-PCR PSCA阳性独立提示接受ADT治疗的晚期PCa患者存在AIP。
Recent studies show that prostate stem cell antigen (PSCA) mRNA positivity in peripheral blood correlates with disease progression in prostate cancer (PCa). Our study is to evaluate the association between peripheral blood PSCA status and androgen‐independent progression (AIP) in a cohort of patients with advanced PCa under androgen deprivation therapy (ADT). PSCA mRNA was measured by reverse transcriptase polymerase chain reaction (RT‐PCR) assay in peripheral blood samples from 116 patients with locally advanced or metastatic PCa who were treated with primary ADT and from 40 healthy controls. The Kaplan–Meier and the Cox proportional hazards methods were used to assess potential predictors of AIP. Pretreatment RT‐PCR‐PSCA was positive in 37 (31.9%) of 116 patients. All healthy volunteers were negative for PSCA mRNA. Although seven (14.9%) of 47 patients with Gleason score ≤7 were PSCA positive, 30 (43.5%) of 69 patients with Gleason score >7 were PSCA positive (p = 0.016). PSCA mRNA was detected in 28 (58.3%) of 48 patients with metastatic PCa, compared to nine (13.2%) of 68 patients with locally advanced disease (p = 0.012). AIP developed in 59 (50.9%) patients during a median follow‐up period of 35.4 months (range: 4–78 months). Patients with PSCA negativity experienced significantly longer remissions compared to those with PSCA positivity (log‐rank test: p < 0.001). Multivariate Cox regression analysis further demonstrated that PSCA positivity had a significantly increased risk of AIP (HR = 4.303, 95% CI: 3.761–7.482, p < 0.001). Pretreatment RT‐PCR PSCA positivity in peripheral blood independently signals the presence of AIP in patients with advanced PCa treated with ADT.